Altimmune IncNASDAQ:ALT
- LAST PRICE7.6800
- TODAY'S CHANGE (%)0.2200 (2.9491%)
- Bid / Lots7.6800/ 1
- Ask / Lots7.7400/ 2
- Open / Previous Close7.4500 / 7.4600
- Day Range
- 52 Week Range
- Volume1,938,403
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | ALT |
|---|---|---|
| 09:32 ET | 35272 | 7.4301 |
| 09:33 ET | 20007 | 7.4599 |
| 09:35 ET | 5167 | 7.47 |
| 09:37 ET | 41393 | 7.4101 |
| 09:39 ET | 11427 | 7.44 |
| 09:42 ET | 10224 | 7.44 |
| 09:44 ET | 21680 | 7.39 |
| 09:46 ET | 31570 | 7.43 |
| 09:48 ET | 15719 | 7.46 |
| 09:50 ET | 15125 | 7.47 |
| 09:51 ET | 8485 | 7.45 |
| 09:53 ET | 4405 | 7.455 |
| 09:55 ET | 2256 | 7.46 |
| 09:57 ET | 6081 | 7.47 |
| 10:00 ET | 10234 | 7.485 |
| 10:02 ET | 8352 | 7.48 |
| 10:04 ET | 8070 | 7.46 |
| 10:06 ET | 6928 | 7.4109 |
| 10:08 ET | 27534 | 7.3677 |
| 10:09 ET | 11829 | 7.3898 |
| 10:11 ET | 14101 | 7.425 |
| 10:13 ET | 10500 | 7.485 |
| 10:15 ET | 5310 | 7.49 |
| 10:18 ET | 22591 | 7.546 |
| 10:20 ET | 23106 | 7.52 |
| 10:22 ET | 12798 | 7.51 |
| 10:24 ET | 31859 | 7.52 |
| 10:26 ET | 6247 | 7.5498 |
| 10:27 ET | 4126 | 7.545 |
| 10:29 ET | 5683 | 7.59 |
| 10:31 ET | 23189 | 7.614 |
| 10:33 ET | 20702 | 7.62 |
| 10:36 ET | 8140 | 7.63 |
| 10:38 ET | 9115 | 7.631199 |
| 10:40 ET | 8251 | 7.6007 |
| 10:42 ET | 6838 | 7.5692 |
| 10:44 ET | 13482 | 7.58 |
| 10:45 ET | 5634 | 7.54 |
| 10:47 ET | 3829 | 7.5345 |
| 10:49 ET | 14984 | 7.52 |
| 10:51 ET | 5400 | 7.55 |
| 10:54 ET | 10576 | 7.55 |
| 10:56 ET | 13970 | 7.56 |
| 10:58 ET | 4000 | 7.5297 |
| 11:00 ET | 4982 | 7.52 |
| 11:02 ET | 2100 | 7.51 |
| 11:03 ET | 5637 | 7.485 |
| 11:05 ET | 4288 | 7.5 |
| 11:07 ET | 8300 | 7.53 |
| 11:09 ET | 3359 | 7.51 |
| 11:12 ET | 2680 | 7.4939 |
| 11:14 ET | 5553 | 7.52 |
| 11:16 ET | 2650 | 7.53 |
| 11:18 ET | 4132 | 7.53 |
| 11:20 ET | 2565 | 7.55 |
| 11:21 ET | 1924 | 7.5445 |
| 11:23 ET | 1600 | 7.54 |
| 11:25 ET | 10184 | 7.515 |
| 11:27 ET | 3353 | 7.55 |
| 11:30 ET | 3178 | 7.55 |
| 11:32 ET | 1569 | 7.53 |
| 11:34 ET | 3800 | 7.515 |
| 11:36 ET | 2710 | 7.531094 |
| 11:38 ET | 9203 | 7.54 |
| 11:39 ET | 4866 | 7.565 |
| 11:41 ET | 5585 | 7.59 |
| 11:43 ET | 8620 | 7.56 |
| 11:45 ET | 825 | 7.555 |
| 11:48 ET | 2400 | 7.55 |
| 11:50 ET | 3950 | 7.53 |
| 11:52 ET | 1027 | 7.525 |
| 11:54 ET | 7335 | 7.51 |
| 11:56 ET | 1700 | 7.48 |
| 11:57 ET | 4943 | 7.465 |
| 11:59 ET | 15650 | 7.415 |
| 12:01 ET | 21660 | 7.485 |
| 12:03 ET | 16254 | 7.4673 |
| 12:06 ET | 1100 | 7.47 |
| 12:08 ET | 5425 | 7.44 |
| 12:10 ET | 1118 | 7.43 |
| 12:12 ET | 8298 | 7.45 |
| 12:14 ET | 18551 | 7.42 |
| 12:15 ET | 13583 | 7.415 |
| 12:17 ET | 4884 | 7.415 |
| 12:19 ET | 450 | 7.42 |
| 12:21 ET | 10479 | 7.44 |
| 12:24 ET | 11544 | 7.44 |
| 12:26 ET | 2800 | 7.45 |
| 12:28 ET | 3511 | 7.455 |
| 12:30 ET | 4600 | 7.47 |
| 12:32 ET | 7538 | 7.46 |
| 12:33 ET | 8330 | 7.47 |
| 12:35 ET | 4692 | 7.49 |
| 12:37 ET | 6800 | 7.48 |
| 12:39 ET | 2147 | 7.485 |
| 12:42 ET | 2479 | 7.505 |
| 12:44 ET | 1853 | 7.4988 |
| 12:46 ET | 4000 | 7.5 |
| 12:48 ET | 4600 | 7.49 |
| 12:50 ET | 22324 | 7.49 |
| 12:51 ET | 5140 | 7.48 |
| 12:53 ET | 1800 | 7.49 |
| 12:55 ET | 900 | 7.495 |
| 12:57 ET | 5943 | 7.4899 |
| 01:00 ET | 4680 | 7.5009 |
| 01:02 ET | 2734 | 7.48 |
| 01:04 ET | 3550 | 7.495 |
| 01:06 ET | 433 | 7.5 |
| 01:08 ET | 8722 | 7.47 |
| 01:09 ET | 3900 | 7.455 |
| 01:11 ET | 1768 | 7.45 |
| 01:13 ET | 2463 | 7.455 |
| 01:15 ET | 4900 | 7.4446 |
| 01:18 ET | 25178 | 7.47 |
| 01:20 ET | 829 | 7.47 |
| 01:22 ET | 1600 | 7.475 |
| 01:24 ET | 1886 | 7.45 |
| 01:26 ET | 968 | 7.45 |
| 01:27 ET | 4500 | 7.495 |
| 01:29 ET | 10774 | 7.5154 |
| 01:31 ET | 11322 | 7.5 |
| 01:33 ET | 2039 | 7.51 |
| 01:36 ET | 1630 | 7.515 |
| 01:38 ET | 2487 | 7.5388 |
| 01:40 ET | 12450 | 7.5258 |
| 01:42 ET | 3358 | 7.5 |
| 01:44 ET | 2189 | 7.5101 |
| 01:45 ET | 10580 | 7.53 |
| 01:47 ET | 5700 | 7.525 |
| 01:49 ET | 3833 | 7.5199 |
| 01:51 ET | 572 | 7.5199 |
| 01:54 ET | 8039 | 7.51 |
| 01:56 ET | 900 | 7.5 |
| 01:58 ET | 1225 | 7.52 |
| 02:00 ET | 4140 | 7.496 |
| 02:02 ET | 13885 | 7.46 |
| 02:03 ET | 2335 | 7.46 |
| 02:05 ET | 13405 | 7.48 |
| 02:07 ET | 1670 | 7.48 |
| 02:09 ET | 1600 | 7.49 |
| 02:12 ET | 2379 | 7.48 |
| 02:14 ET | 2915 | 7.46 |
| 02:16 ET | 800 | 7.46 |
| 02:18 ET | 2700 | 7.46 |
| 02:20 ET | 1300 | 7.47 |
| 02:21 ET | 4938 | 7.47 |
| 02:23 ET | 1734 | 7.47 |
| 02:25 ET | 6100 | 7.48 |
| 02:27 ET | 4658 | 7.4999 |
| 02:30 ET | 7338 | 7.51 |
| 02:32 ET | 2518 | 7.525 |
| 02:34 ET | 4375 | 7.535 |
| 02:36 ET | 3900 | 7.54 |
| 02:38 ET | 8330 | 7.56 |
| 02:39 ET | 15100 | 7.585 |
| 02:41 ET | 15038 | 7.61 |
| 02:43 ET | 13254 | 7.57 |
| 02:45 ET | 3820 | 7.5818 |
| 02:48 ET | 3040 | 7.585 |
| 02:50 ET | 902 | 7.5899 |
| 02:52 ET | 5158 | 7.6 |
| 02:54 ET | 7121 | 7.59 |
| 02:56 ET | 2487 | 7.59 |
| 02:57 ET | 5800 | 7.59 |
| 02:59 ET | 2600 | 7.565 |
| 03:01 ET | 4572 | 7.57 |
| 03:03 ET | 1906 | 7.56 |
| 03:06 ET | 16053 | 7.59 |
| 03:08 ET | 1949 | 7.601 |
| 03:10 ET | 5376 | 7.58 |
| 03:12 ET | 1996 | 7.57 |
| 03:14 ET | 11033 | 7.545 |
| 03:15 ET | 2086 | 7.5559 |
| 03:17 ET | 4812 | 7.57 |
| 03:19 ET | 7200 | 7.5798 |
| 03:21 ET | 6245 | 7.56 |
| 03:24 ET | 3200 | 7.559 |
| 03:26 ET | 3800 | 7.56 |
| 03:28 ET | 5700 | 7.57 |
| 03:30 ET | 1850 | 7.565 |
| 03:32 ET | 2492 | 7.56 |
| 03:33 ET | 1454 | 7.57 |
| 03:35 ET | 4808 | 7.58 |
| 03:37 ET | 300 | 7.589 |
| 03:39 ET | 4100 | 7.605 |
| 03:42 ET | 3647 | 7.6061 |
| 03:44 ET | 14935 | 7.6192 |
| 03:46 ET | 9936 | 7.615 |
| 03:48 ET | 4710 | 7.605 |
| 03:50 ET | 12951 | 7.605 |
| 03:51 ET | 10801 | 7.625 |
| 03:53 ET | 19825 | 7.62 |
| 03:55 ET | 66510 | 7.675 |
| 03:57 ET | 23866 | 7.645 |
| 04:00 ET | 164306 | 7.68 |
Nov 7, 2024
Altimmune Announces Successful Completion of End-of-Phase 2 Meeting with FDA for Pemvidutide in the Treatment of Obesity, from 7:30AM ET on Thursday Nov 07, 2024 by Dow Jones
7:30AM ET on Thursday Nov 07, 2024 by Dow Jones
Nov 6, 2024
Altimmune to Participate at Two Upcoming Investor Conferences, from 7:30AM ET on Wednesday Nov 06, 2024 by Dow Jones
7:30AM ET on Wednesday Nov 06, 2024 by Dow Jones
Nov 4, 2024
Altimmune to Report Third Quarter 2024 Financial Results and Provide Business Update on November 12, 2024, from 7:30AM ET on Monday Nov 04, 2024 by Dow Jones
7:30AM ET on Monday Nov 04, 2024 by Dow Jones
Oct 15, 2024
Altimmune to Present New Data on the Lipidomic Profile in Subjects Treated with Pemvidutide at The Liver Meeting(R) 2024, from 8:00AM ET on Tuesday Oct 15, 2024 by Dow Jones
8:00AM ET on Tuesday Oct 15, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Altimmune Inc | 545.8M | -4.7x | --- |
Q32 Bio Inc | 546.2M | -2.8x | --- |
Aura Biosciences Inc | 539.7M | -6.1x | --- |
Kalvista Pharmaceuticals Inc | 560.0M | -3.2x | --- |
Monte Rosa Therapeutics Inc | 568.3M | -5.1x | --- |
Larimar Therapeutics Inc | 569.2M | -7.7x | --- |
Company Information
Altimmune, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for obesity and liver diseases. The Company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and metabolic dysfunction-associated steatohepatitis (MASH). The Company has completed the MOMENTUM Phase II obesity trial and is being studied in the IMPACT Phase IIb MASH trial. It is also developing HepTcell, an immunotherapeutic product candidate for patients chronically infected with the hepatitis B virus (HBV). The Company has completed the enrollment in its Phase II clinical trial of HepTcell. Its product candidates are based on its proprietary platform technologies, such as EuPort-based Peptide Technology and Synthetic Peptide Technology-Densigen. The Company’s wholly owned subsidiaries include Altimmune, LLC, Altimmune UK, Limited, Spitfire Pharma, LLC and Altimmune AU Pty, Limited.
Contact Information
- Headquarters
- 910 Clopper Road, Suite 201SGAITHERSBURG, MD, United States 20878-1361
- Phone
- 240-654-1450
- Fax
- 302-674-5266
Executives
- Independent Chairman of the Board
- Mitchel Sayare
- President, Chief Executive Officer, Director
- Vipin Garg
- Acting Chief Financial Officer
- Andrew Shutterly
- Chief Scientific Officer
- M. Scot Roberts
- Chief Medical Officer
- M. Scott Harris
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $545.8M |
|---|---|
Revenue (TTM) | $409.0K |
Shares Outstanding | 71.1M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.10 |
EPS | $-1.62 |
Book Value | $2.75 |
P/E Ratio | -4.7x |
Price/Sales (TTM) | 1,334.5 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -26,822.01% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
